点击显示 收起
Departments of Anesthesiology (V.Y., A.V.G., N.G., D.M.D., C.N.S., A.E.M.), Physiology and Functional Genomics (C.S.)
the McKnight Brain Institute (C.S., N.G., D.M.D., A.E.M.), University of Florida, Gainesville, Florida
Abstract
An increasing body of evidence supports the hypothesis that diminished function of N-methyl-D-aspartate (NMDA) receptors and the associated increase in glutamate release and overstimulation of -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors are critical elements of the pathophysiology of schizophrenia. Here, we describe a halogenated derivative of the aromatic amino acid L-phenylalanine that 1) activates NMDA receptors, 2) depresses presynaptic glutamate release, and 3) blocks AMPA/kainate receptors. The experiments were conducted in rat cerebrocortical cultured neurons by using the patch-clamp technique. 3,5-Dibromo-L-phenylalanine (3,5-DBr-L-Phe) augmented NMDA miniature excitatory postsynaptic currents (mEPSCs) and activated the steady-state current, effects that were eliminated by NMDA receptor antagonists DL-2-amino-5-phosphonopentanoic acid and MK-801 (dizocilpine maleate; 5H-dibenzo[a,d]cyclohepten-5,10-imine). 3,5-DBr-L-Phe was a partial agonist at the glutamate-binding site of NMDA receptors with an EC50 of 331.6 ± 78.6 e and with an efficacy of 30.5 ± 4.7% compared with NMDA. 3,5-DBr-L-Phe depressed both amplitude and frequency of AMPA/kainate mEPSCs. The IC50 of 3,5-DBr-L-Phe to inhibit AMPA/kainate mEPSC frequency was 29.4 ± 4.3 e. 3,5-DBr-L-Phe significantly decreased paired pulse depression of AMPA/kainate EPSCs and attenuated current activated by AMPA with higher efficacy at lower concentration of AMPA. 3,5-DBr-L-Phe neither affected GABA miniature inhibitory postsynaptic currents nor elicited action potentials. By enhancing NMDA receptor function, reducing glutamate release and blocking AMPA/kainate receptors 3,5-DBr-L-Phe represents a new type of polyvalent modulator of glutamatergic synaptic transmission with potential therapeutic applications.
In vitro, in vivo, and clinical evidence indicates that disturbed glutamatergic synaptic transmission may be a critical element in the pathophysiology of several brain disorders, including schizophrenia (Konradia and Heckersa, 2003; Moghaddam and Jackson, 2003). Abnormal glutamatergic neurotransmission has been reported in animal models of schizophrenia as well as in human post-mortem and glutamate receptor antagonist studies (Hirsch and Weinberger, 2003; Konradia and Heckersa, 2003; Moghaddam and Jackson, 2003). Noncompetitive antagonists of NMDA receptors (MK-801 and phencyclidine) increase the locomotor activity of animals and induce stereotyped behavior characteristic of human schizophrenia (Lipska and Weinberger, 2000). Likewise, NMDA receptor antagonists produce in otherwise healthy humans positive and negative symptoms of schizophrenia and exacerbate those in schizophrenic patients (Krystal et al., 1994; Jentsch and Roth, 1999). In addition to decreased NMDA receptor function, changes in glutamatergic transmission characteristic of schizophrenia include increased glutamate release and overstimulation of non-NMDA (AMPA/kainate) receptors (Moghaddam et al., 1997). Consistent with this hypothesis are findings showing an increase in the number of NMDA receptor subunits NR1 in cortical regions and a decrease in the expression of AMPA/kainate receptors in the hippocampus of schizophrenics (Meador-Woodruff and Healy, 2000). The observed decrease in AMPA/kainate receptors may be a down-regulation secondary to increased glutamate release, which in turn results from decreased stimulation of the GABA-ergic system caused by hypofunction of NMDA receptors (Moghaddam et al., 1997; Greene 2001).
Therefore, to possess antipsychotic properties, potential pharmacological candidates with glutamatergic action should either augment NMDA receptor function, diminish glutamate release, or block postsynaptic AMPA/kainate receptors. Consistent with this contention, agonists of the glycine-binding site of NMDA receptors alleviate not only negative but also positive symptoms of schizophrenia and improve cognitive function (Heresco-Levy and Javitt, 2004). Antagonists of AMPA/kainate receptors and agonists for group II metabotropic glutamate receptors reverse the psychotic effects of phencyclidine and inhibit conditioned avoidance responses and amphetamine-induced hyperactivity (Moghaddam and Adams, 1998; Lorrain et al., 2003; Takahata and Moghaddam, 2003). Despite the availability of many types of antipsychotic drugs the search for new efficacious agents without unwanted side effects remains a high priority in the treatment of schizophrenia (Hyman and Fenton, 2003; Moghaddam, 2003).
Here, we describe a compound that simultaneously produces all three desirable actions on glutamatergic synaptic transmission. During investigation of the cellular mechanisms of brain dysfunction seen in phenylketonuria, we found that L-Phe selectively depresses glutamatergic synaptic transmission by a combination of pre- and postsynaptic actions (Glushakov et al., 2002, 2003). Specifically, L-Phe depresses glutamatergic synaptic transmission by 1) competing for the glycine-binding site of NMDA receptors, 2) competing for the glutamate-binding site of AMPA/kainate receptors, and 3) attenuating glutamate release. The relative contribution of each individual mechanism to the antiglutamatergic effect of L-Phe can be modified by creating halogenated derivatives of the molecule (Kagiyama et al., 2004). This provides the opportunity to select/synthesize ligands with specific patterns of glutamatergic action. The halogenated derivative of L-Phe, 3,5-dibromo-L-phenylalanine (3,5-DBr-L-Phe) acts as partial agonist of NMDA receptors, inhibits glutamate release, and depresses AMPA/kainate receptor activity, and importantly, does not influence activity of voltage-operated ionic channels.
Materials and Methods
All experiments were approved by the University of Florida Animal Care and Use Committee.
Neuronal Cultures. Cerebral cortices were dissected from newborn rats and treated with 0.25% trypsin to dissociate the cells. Dissociated cells were resuspended in Dulbecco's modified Eagle's medium containing 10% plasma-derived horse serum and were plated in poly-L-lysine-coated, 35-mm plastic tissue culture dishes (3.0 x 106 cells/dish/2 ml of medium) (Nalge Nunc, Naperville, IL). Cultures were maintained in an atmosphere of 5% CO2, 95% air.
Electrophysiological Recordings. Voltage- and current-clamp recordings of membrane ionic currents and potentials were conducted by using Axopatch 200B and Axoclamp 1B amplifiers (Axon Instruments Inc., Union City, CA). The perforated nystatin- and gramicidin-based patch-clamp recording techniques were used in some cases to reduce nonspecific rundown of intracellular processes. Neurons were used for electrophysiological recordings between 12 and 27 days in vitro. If a neuron showed either a marked change in holding current or a noticeable alteration in amplitude or shape of capacitance transients during the experiment, the data from that neuron were discarded. Patch microelectrodes were pulled from 1.5-mm borosilicate glass tubing using a two-stage vertical pipette puller (Narishige, East Meadow, NY). When filled with recording solution, patch microelectrodes had a resistance of 3 to 5 M. For rapid application of agonist-containing solutions to neurons, the SF-77B system (Warner Instrument, Hamden, CT) was used. Otherwise, a slower exchange of extracellular solution was done using a customized system. The slow onset of activation of 3eC5-DBr-L-Phe-induced current seen in some figures is related to slow exchange of extracellular solution and not to a gradual onset of 3,5-DBr-L-Phe-induced activation of NMDA receptors.
The miniature EPSCs were recorded in TTX-containing (0.3eC1 e) extracellular solution at Vh = eC60 mV. In NMDA receptor-mediated mEPSC recordings, Mg2+ was omitted from the extracellular solution. To isolate the NMDA component of glutamate receptor-mediated currents, the non-NMDA (AMPA/kainate) receptor antagonist NBQX (10eC20 e) was added to extracellular solutions. Conversely, to isolate the non-NMDA receptor-mediated currents, the experiments were performed in the presence of NMDA receptor channel blocker MK-801 (5eC10 e) or in the presence of the NMDA receptor antagonist AP-5 (20 e). Strychnine (1 e) and picrotoxin (100 e) were added to the extracellular solution to block glycine and GABA receptors, respectively. The basic extracellular solution contained 140 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 11 mM glucose. The pH of the extracellular solution was adjusted to 7.4 using NaOH. The main solution for filling the patch electrodes contained 135 mM Cs gluconate, 5 mM NaCl, 10 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 11 mM EGTA, 10 mM HEPES, 2 mM Na2ATP, and 0.2 mM Na2GTP. The pH of the intracellular solution was adjusted to 7.4 using CsOH. To record GABA receptor-mediated miniature inhibitory postsynaptic currents (mIPSCs), 100 e picrotoxin in the extracellular solution and 135 mM Cs gluconate in the intrapipette solution were replaced with 5 e NBQX and 135 mM KCl, respectively. Various concentrations of 3,5-DBr-L-Phe, NMDA, AMPA, and glycine were added to the extracellular solution according to the protocols described. 3,5-DBr-L-Phe was obtained from Showa Denko K.K. (Kawasaki, Japan). All other compounds were purchased from Sigma-Aldrich (St. Louis, MO) and Tocris Cookson Inc. (Ellisville, MO).
The digitized data were analyzed off-line using the Mini-Analysis Program (Synaptosoft, Leonia, NJ) or pCLAMP9 (Axon Instruments Inc.). Miniature EPSCs were identified and confirmed by analyzing the rise time, decay time, and waveform of each individual spontaneous event.
General Data Analysis. Values are reported as mean ± S.E.M. Before parametric testing, the assumption of normality was validated using the Kolmogorov-Smirnov test with Lilliefor's correction (SPSS version 10; SPSS Inc., Chicago, IL). Multiple comparisons among groups were analyzed using analysis of variance (two- or one-way repeated measures with two- or one-way replication where appropriate) followed by Student-Newman-Keuls testing. Single comparisons were analyzed using a two-tailed Student's t test. A P < 0.05 was considered significant.
Results
Effect of 3,5-DBr-L-Phe on NMDA Receptor Function. The NMDA receptor-mediated mEPSCs in rat cultured neurons were recorded in Mg2+-free extracellular solution in the presence of AMPA/kainate, glycine, and GABA receptor blockers and were analyzed as fluctuating background inward current (noise). 3,5-DBr-L-Phe, added to the extracellular solution, increased this current in a concentration-dependent manner (Fig. 1A). The augmenting effect of 3,5-DBr-L-Phe was detectable at concentrations as low as 10 e and reached its maximum at concentrations of 1000 e. The effect of 3,5-DBr-L-Phe at low concentrations (less than 30 e) manifested as potentiation of the mEPSCs, whereas at higher concentrations, 3,5-DBr-L-Phe activated the steady-state inward current (Fig. 1A). The concentration of 3,5-DBr-L-Phe required to produce half-maximal effect (EC50) was 331.6 ± 78.6 e. The concentration-response relationships for 3,5-DBr-L-Phe to activate total steady-state and fluctuating background inward currents are shown in Fig. 1, B and C, respectively. Compared with NMDA-activated current, 3,5-DBr-L-Phe-activated current had a similar onset and reverted to baseline on washout of 3,5-DBr-L-Phe (Fig. 1A). The NMDA receptor antagonist AP-5 and the NMDA receptor channel blocker MK-801 (not shown) completely blocked current activated by 3,5-DBr-L-Phe (Fig. 1D).
To elucidate whether 3,5-DBr-L-Phe interacts with the glutamate- or glycine-binding sites on NMDA receptors, we measured its effects in the presence of different concentrations of glycine, glutamate, and NMDA added to the extracellular solution. A 100-fold increase in concentration of glycine from 0.1 to 10 e did not prevent the augmenting effect of 3,5-DBr-L-Phe on NMDA receptor-mediated current (Fig. 2A). 3,5-DBr-L-Phe (100 e) activated NMDA receptor-mediated current of 67.4 ± 16.4 and 144.4 ± 32.7 pA in the presence of 0.1 and 10 e glycine, respectively. To obtain further evidence for whether 3,5-DBr-L-Phe interacts with the glycine-binding site of NMDA receptors, the dose-response curves for glycine to modulate NMDA current were generated in the absence and presence of 3,5-DBr-L-Phe. These dose-response curves overlapped (Fig. 2B), indicating that augmentation of NMDA receptor current by 3,5-DBr-L-Phe cannot be explained by its interaction with the glycine-binding site of NMDA receptors. The effect of 3,5-DBr-L-Phe on NMDA receptor function, however, did depend on the concentration of glutamate or NMDA. At low concentrations of glutamate and NMDA, total NMDA receptor-mediated current activated by glutamate or NMDA combined with 3,5-DBr-L-Phe was larger than the current recorded in response to application of glutamate or NMDA only. In contrast, combined current, activated by both 3,5-DBr-L-Phe and higher concentration of glutamate or NMDA, was either smaller or similar to the current recorded in the presence of glutamate or NMDA only (Fig. 2, C and D). Comparison of the concentration-response relationships for 3,5-DBr-L-Phe and NMDA to activate NMDA receptor-mediated currents showed that efficacy for 3,5-DBr-L-Phe was 30.5 ± 4.7% compared with NMDA (Fig. 2, E and F). Similar efficacy for 3,5-DBr-L-Phe was observed when instead of NMDA glutamate was used as agonist (data not shown). These results demonstrate that 3,5-DBr-L-Phe acts as a partial agonist of the glutamate-binding site of NMDA receptors.
Effect of 3,5-DBr-L-Phe on Glutamate Release and AMPA/Kainate Receptor Function. To isolate the non-NMDA receptor-mediated EPSCs, experiments were performed in the presence of NMDA receptor channel blocker MK-801 (5eC10 e) or in the presence of the NMDA receptor antagonist AP-5 (20 e). Strychnine (1 e) and 100 e picrotoxin were added to the extracellular solution to block glycine and GABA receptors, respectively. Further addition of the non-NMDA receptor antagonist NBQX (10 e) abolished all postsynaptic currents, indicating that the recorded mEPSCs were mediated through activation of a non-NMDA receptor (AMPA/kainate) subtype of glutamate receptors. A typical record of membrane ionic current under such conditions is illustrated in Fig. 3A. In contrast to NMDA receptor-mediated currents, 3,5-DBr-L-Phe depressed both the frequency and amplitude of AMPA/kainate receptor-mediated mEPSCs. The frequency and amplitude of AMPA/kainate receptor-mediated mEPSCs were depressed from 2.4 ± 0.7 Hz and 20.0 ± 6.6 pA in control to 0.6 ± 0.2 Hz and 12.8 ± 3.9 pA in the presence of 100 e 3,5-DBr-L-Phe, respectively (Fig. 3, B and C). The effect of 3,5-DBr-L-Phe had a fast onset and was reversible on washout. A clear reduction in the frequency and amplitude of detected mEPSCs was seen within seconds after application of 3,5-DBr-L-Phe. The depressant effect of 3,5-DBr-L-Phe on AMPA/kainate-mediated mEPSCs was concentration-dependent. Analysis of the concentration-response curve for the effect of 3,5-DBr-L-Phe to inhibit mEPSC frequency using a nonlinear logistic regression technique showed that the concentration of 3,5-DBr-L-Phe required to depress non-NMDA receptor-mediated mEP-SCs by half (IC50) was 29.4 ± 4.3 e. The finding that 3,5-DBr-L-Phe attenuates both the frequency and the amplitude of AMPA/kainate receptor-mediated mEPSCs indicates that 3,5-DBr-L-Phe may produce both pre- and postsynaptic effects.
To determine whether 3,5-DBr-L-Phe changes the probability of glutamate release, the extent of paired pulse depression for AMPA/kainate receptor-mediated component of EP-SCs and its changes after application of 3,5-DBr-L-Phe was established. Low-density areas in dishes with cultured cells (two to five neurons in 400-e-diameter view-field) were selected for the experiments. Synaptic responses were evoked by applying voltage pulses (0.2eC1 ms, 20eC90 V) to an extracellular electrode (a patch electrode filled with the extracellular solution) positioned in the vicinity of the presynaptic neuron soma or neurite (Fig. 4A). As a quantitative estimate of paired pulse depression, the paired pulse ratio, [i.e., the ratio of the amplitude of the second EPSC in the pair to that of the first (EPSC2/EPSC1)] was estimated. Application of 100 e 3,5-DBr-L-Phe decreased the amplitude of single evoked EPSCs (first response in a paired pulse experiment) in cerebrocortical neurons by 47.5 ± 2.9% (Fig. 4B). Although the EPSC kinetics did not seem to change, 3,5-DBr-L-Phe decreased the paired pulse ratio by 41.4 ± 15.0%. These data suggest that a reduced probability of synaptic vesicle release may contribute to the inhibitory effect of 3,5-DBr-L-Phe on excitatory transmission at these synapses.
To assess whether 3,5-DBr-L-Phe may also depress activity of postsynaptic AMPA/kainate receptors, we investigated the effect of 3,5-DBr-L-Phe on current activated by AMPA. AMPA (3 e) activated a rapidly rising inward current (i.e., IAMPA) that was depressed by 3,5-DBr-L-Phe (Fig. 4C). The effect of 3,5-DBr-L-Phe on IAMPA was concentration-dependent and reversible upon washout of the drug. The concentration-response relationships for 3,5-DBr-L-Phe to depress IAMPA obtained at two different concentrations of AMPA are shown in Fig. 4D. The increase in the concentration of AMPA from 3 to 10 e markedly shifted the concentration-response relationship for 3,5-DBr-L-Phe to depress IAMPA rightward (Fig. 4D). The IC50 values of 3,5-DBr-L-Phe in the presence of 3 and 10 e AMPA were 294.4 ± 8.9 and 1140.1 ± 54.6 e, respectively. These results indicate that 3,5-DBr-L-Phe most probably acts as a competitive inhibitor of the glutamate-binding site on the AMPA receptors.
Effect of 3,5-DBr-L-Phe on GABA-ergic Transmission and Elicited Action Potentials. GABA receptor-mediated mIPSCs were recorded in the presence of 5 e MK-801, 10 e NBQX, and 1 e strychnine to block NMDA, AMPA/kainate, and glycine receptors, respectively. A typical record of membrane ionic current under such conditions is illustrated in Fig. 5A. 3,5-DBr-L-Phe (100 e) significantly changed neither the frequency nor the amplitude of GABA receptor-mediated mIPSCs. The frequency and amplitude of GABA receptor-mediated mIPSCs were depressed from 1.0 ± 0.2 Hz and 25.1 ± 2.3 pA in control to 0.8 ± 0.2 Hz and 24.2 ± 1.6 pA in the presence of 100 e 3,5-DBr-L-Phe, respectively (Fig. 5, A and B). Likewise, 100 e 3,5-DBr-L-Phe did not cause any changes in elicited action potentials (Fig. 5C), indicating lack of the effect of 3,5-DBr-L-Phe on voltage-operated ionic channels.
Discussion
The results of the current study clearly demonstrate that 3,5-DBr-L-Phe produces a unique combination of actions on excitatory glutamatergic synaptic transmission in rat cerebrocortical cultured neurons. Specifically, 3,5-DBr-L-Phe activates NMDA receptor-mediated current, depresses activity of non-NMDA (AMPA/kainate) subtype of glutamate receptors, and diminishes presynaptic glutamate release. Such differential modulation of glutamatergic synaptic transmission may be beneficial in brain disorders characterized by alterations in the glutamate system.
Mechanism of Action. Current activated by 3,5-DBr-L-Phe was blocked by the specific NMDA receptor antagonists AP-5 and MK-801. These and other experimental evidence indicate that 3,5-DBr-L-Phe acts as agonist of NMDA receptors. NMDA receptors require two coagonists, glutamate and glycine, for their activation. The binding sites for glycine and glutamate are located on subunits 1 and 2, respectively (Laube et al., 1997). Previously, we have demonstrated that L-Phe depressed NMDA receptor function by competing for the glycine-binding site of NMDA receptors and depressed non-NMDA receptor activity by competing for the glutamate-binding site of these receptors (Glushakov et al., 2002, 2003). Similar to L-Phe, 3,5-DBr-L-Phe also is a competitive antagonist of AMPA/kainate receptors. Surprisingly, halogenation of the L-Phe molecule not only reversed its effect (activation versus depression) but also changed the site of its interaction with the NMDA receptors (glutamate-binding site versus glycine-binding site). Thus, the activating effect of 3,5-DBr-L-Phe on NMDA receptor function did not depend on concentration of glycine. Increases in the concentration of glycine augmented the 3,5-DBr-L-Phe-activated current as would be expected from an increased concentration of coagonist. On the other hand, the activating effect of 3,5-DBr-L-Phe on NMDA receptor function depended on the concentration of glutamate or NMDA added to the extracellular solution. The total current activated by 3,5-DBr-L-Phe and low concentrations of the agonists was bigger than the current activated by glutamate or NMDA only. The opposite changes in NMDA receptor-mediated current took place at higher concentrations of glutamate or NMDA. It is noteworthy that the maximal current activated by 3,5-DBr-L-Phe was approximately 30% of the maximal current activated by NMDA or glutamate. Together, these findings support the notion that 3,5-DBr-L-Phe acts as a partial NMDA receptor agonist at the glutamate-binding site.
Our results indicate that 3,5-DBr-L-Phe has a postsynaptic effect on non-NMDAR (AMPA/kainate)-mediated events as well. 3,5-DBr-L-Phe depressed the amplitude of non-NMDAR-mediated mEPSCs and the current activated by exogenous AMPA. Increases in the concentration of AMPA shifted the concentration-response curve for the effect of 3,5-DBr-L-Phe on IAMPA rightward. This finding suggests that the glutamate-binding site on the AMPA receptor is a possible target for the inhibitory action of 3,5-DBr-L-Phe. The postsynaptic effects of 3,5-DBr-L-Phe on non-NMDA receptors may be further augmented by the presynaptic action of 3,5-DBr-L-Phe. Although the postsynaptic effects of 3,5-DBr-L-Phe can reduce the frequency of AMPA/kainate receptor-mediated mEPSCs by decreasing the mEPSC amplitude of some events below the threshold for detection, the predomiynant depression of mEPSC frequency over mEPSC amplitude strongly suggests a presynaptic action based on a decreased probability of glutamate release. The 3,5-DBr-L-Phe-induced decrease in the frequency of AMPA/kainate mEPSCs in combination with the decreased extent of the paired pulse depression for elicited AMPA/kainate EPSCs in the presence of 3,5-DBr-L-Phe independently support the possibility that 3,5-DBr-L-Phe also depresses of neurotransmitter release.
Elucidation of the mechanism(s) of 3,5-DBr-L-Phe-induced depression of neurotransmitter release requires further investigation. Because mEPSCs, unlike elicited EPSCs, do not depend on Ca2+ entry, a reduction of Ca2+ influx into the presynaptic terminal cannot explain the action of 3,5-DBr-L-Phe. In addition, absence of any effect of 3,5-DBr-L-Phe on elicited action potentials indicates that this agent is unlikely to affect initiation of Ca2+ influx into the presynaptic terminal by action potentials. The failure of 3,5-DBr-L-Phe to affect either elicited action potentials or GABA receptor-mediated mIPSCs further shows that the effects of 3,5-DBr-L-Phe are very specific to glutamatergic transmission. In contrast, the interaction of 3,5-DBr-L-Phe with the glutamate-binding sites on both NMDA and AMPA/kainate receptors shows that among the glutamate-binding sites within the glutamatergic system, 3,5-DBr-L-Phe is less specific. If the limited selectivity for glutamate-binding sites extends to other glutamate receptors, 3,5-DBr-L-Phe may potentially modulate the activity of metabotropic glutamate receptors. A number of studies demonstrate in fact that activation of the metabotropic glutamate receptors, mGlu2/3, depresses glutamate release (Battaglia et al., 1997; Cartmell and Schoepp, 2000). However, in our experiments (data not shown), a selective group II metabotropic glutamate receptor antagonist, LY 341495, did not influence the effect of 5-DBr-L-Phe on the frequency of the AMPA/kainate mEPSCs, indicating that other mechanisms mediate the depressant effect of 3,5-DBr-L-Phe on glutamate release. Elucidation of the mechanisms whereby 3,5-DBr-L-Phe depresses neurotransmitter release requires detailed investigation and will be a subject for our future experiments.
Potential Application of 3,5-DBr-L-Phe. Given the fact that decreased function of NMDA receptors and accompanying increased neurotransmitter release with overactivation of AMPA/kainate receptors are important contributors to the pathophysiology of schizophrenia (Moghaddam et al., 1997; Jentsch and Roth, 1999; Meador-Woodruff and Healy, 2000; Greene, 2001; Hirsch and Weinberger, 2003; Konradia and Heckers, 2003), 3,5-DBr-L-Phe may represent the prototype of a new class of antipsychotic drugs. An important requirement for therapeutic agents with glutamatergic actions is their ability to modulate synaptic transmission, without producing excitotoxicity. 3,5-DBr-L-Phe as a partial agonist of the glutamate-binding site on NMDA receptors should allow normalization of the depressed NMDA receptor activity while preventing overactivation of NMDA receptors by excess glutamate release. In fact, in our preliminary studies we found that 3,5-DBr-L-Phe decreased cell death in neuronal cultures exposed to oxygen glucose deprivation.
Along with activation of NMDA receptors 3,5-DBr-L-Phe depresses glutamate release and postsynaptic AMPA/kainate receptors. Agents that not only augment NMDA receptor function but also regulate glutamate release and activity of AMPA/kainate receptors should potentially be more efficacious in producing antipsychotic effects. Because of the structural relationship between L-Phe and dopamine, there is the possibility of modulation of dopamine receptors by 3,5-DBr-L-Phe as well. L-Phe is the direct precursor of tyrosine, which in turn is metabolized to dopamine. Finally, 3,5-DBr-L-Phe does not alter activity of voltage-operated ionic channels that contribute to generation of action potentials, therefore, it is unlikely that agents with such profile of action would produce significant unwanted effects. Specific investigation of the role of 3,5-DBr-L-Phe in modulation of other neurotransmitter systems and investigation of their antipsychotic properties in animal models of schizophrenia will provide further insight into the possibility of using it as prototype of a new class of antipsychotic agents.
This study was supported by the American Heart Association Florida Affiliate (0355366B), the University of Florida McKnight Brain Institute, and I. Heermann Anesthesia Foundation, Inc.
doi:10.1124/mol.104.005983.
References
Battaglia G, Monn JA, and Schoepp DD (1997) In vivo inhibition of veratridineevoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229: 161eC164.
Cartmell J and Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889eC907.
Glushakov AV, Dennis DM, Morey TE, Sumners C, Cucchiara RF, Seubert CN, and Martynyuk AE (2002) Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria. Mol Psychiatry 7: 359eC367.
Glushakov AV, Dennis DM, Sumners C, Seubert CN, and Martynyuk AE (2003) L-Phenylalanine selectively depresses currents at glutamatergic excitatory synapses. J Neurosci Res 72: 116eC124.
Greene R (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro and psychosis of schizophrenia. Hippocampus 11: 569eC577.
Heresco-Levy U and Javitt DC (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66: 89eC96.
Hirsch SR and Weinberger D (2003) Schizophrenia, Blackwell Publishing, Oxford, UK.
Hyman SE and Fenton WS (2003) Medicine. What are the right targets for psychopharmacology Science (Wash DC) 299: 350eC351.
Jentsch JD and Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201eC225.
Kagiyama T, Glushakov AV, Sumners C, Roose B, Dennis DM, Phillips MI, Ozcan MS, Seubert CN, and Martynyuk AE (2004) Neuroprotective action of halogenated derivatives of L-phenylalanine. Stroke 35: 1192eC1196.
Konradia C and Heckers S (2003) Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97: 153eC179.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 51: 199eC214.
Laube B, Hirai H, Sturgess M, Betz H, and Kuhse J (1997) Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 18: 493eC503.
Lipska BK and Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23: 223eC239.
Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, and Varney MA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697eC706.
Meador-Woodruff JH and Healy DJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31: 288eC294.
Moghaddam B (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron 40: 881eC884.
Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (Wash DC) 281: 1349eC1352.
Moghaddam B, Adams B, Verma A, and Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Neuroscience 17: 2921eC2927.
Moghaddam B and Jackson ME (2003) Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003: 131eC137.
Takahata R and Moghaddam B (2003) Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28: 1117eC1124.